Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Oct;11(5):696-708.
doi: 10.21037/hbsn-21-5.

Comparative effectiveness of medical treatment vs. metabolic surgery for histologically proven non-alcoholic steatohepatitis and fibrosis: a matched network meta-analysis

Adrian T Billeter  1 , Beatrice Reiners  1 , Svenja E Seide  2 , Pascal Probst  1   3 , Eva Kalkum  3 , Christian Rupp  4 , Beat P Müller-Stich  1
Affiliations
Review

Comparative effectiveness of medical treatment vs. metabolic surgery for histologically proven non-alcoholic steatohepatitis and fibrosis: a matched network meta-analysis

Adrian T Billeter et al. Hepatobiliary Surg Nutr. 2022 Oct.

Abstract

Background: Non-alcoholic steatohepatitis (NASH) comprises a major healthcare problem affecting up to 30% of patients with obesity and the associated risk for cardiovascular and liver-related mortality. Several new drugs for NASH-treatment are currently investigated. No study thus far directly compared surgical and non-surgical therapies for NASH. This network meta-analysis compares for the first time the effectiveness of different therapies for NASH using a novel statistical approach.

Methods: The study was conducted according to the PRISMA guidelines for network meta-analysis. PubMed, CENTRAL and Web of Science were searched without restriction of time or language using a validated search strategy. Studies investigating therapies for NASH in adults with liver biopsies at baseline and after at least 12 months were selected. Patients with liver cirrhosis were excluded. Risk of bias was assessed with ROB-2 and ROBINS-I-tools. A novel method for population-adjusted indirect comparison to include and compare single-arm trials was applied. Main outcomes were NASH-resolution and improvement of fibrosis.

Results: Out of 7,913 studies, twelve randomized non-surgical studies and twelve non-randomized surgical trials were included. NASH-resolution after non-surgical intervention was 29% [95% confidence interval (CI): 23-40%] and 79% (95% CI: 72-88%) after surgery. The network meta-analysis showed that surgery had a higher chance of NASH-resolution than medication [odds ratio (OR) =2.68; 95% CI: 1.44-4.97] while drug treatment was superior to placebo (OR =2.24; 95% CI: 1.55-3.24). Surgery (OR =2.18; 95% CI: 1.34-3.56) and medication (OR =1.79; 95% CI: 1.39-2.31) were equally effective to treat fibrosis compared to placebo without difference between them. The results did not change when only new drugs specifically developed for the treatment of NASH were included.

Conclusions: Metabolic surgery has a higher effectiveness for NASH-therapy than medical therapy while both were equally effective regarding improvement of fibrosis. Trials directly comparing surgery with medication must be urgently conducted. Patients with NASH should be informed about surgical treatment options.

Keywords: Non-alcoholic fatty liver disease (NAFLD); fatty liver; metabolic surgery; non-alcoholic steatohepatitis (NASH).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.com/article/view/10.21037/hbsn-21-5/coif). The authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
PRISMA flow chart. NASH, non-alcoholic steatohepatitis.
Figure 2
Figure 2
Matched network meta-analysis for resolution of NASH. NASH, non-alcoholic steatohepatitis; RCT, randomized controlled trial; OR, odds ratio; CI, confidence interval.
Figure 3
Figure 3
Matched network meta-analysis for (A) ballooning and (B) inflammation. RCT, randomized controlled trial; OR, odds ratio; CI, confidence interval.
Figure 4
Figure 4
Matched network meta-analysis for fibrosis. RCT, randomized controlled trial; OR, odds ratio; CI, confidence interval.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Byrne CD, Targher G. NAFLD: a multisystem disease. J Hepatol 2015;62:S47-64. 10.1016/j.jhep.2014.12.012 - DOI - PubMed
    1. Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84. 10.1002/hep.28431 - DOI - PubMed
    1. Bellentani S, Scaglioni F, Marino M, et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-61. 10.1159/000282080 - DOI - PubMed
    1. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. J Hepatol 2006;45:600-6. 10.1016/j.jhep.2006.06.013 - DOI - PubMed
    1. Marchesini G, Brizi M, Bianchi G, et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50. 10.2337/diabetes.50.8.1844 - DOI - PubMed